A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS

Paul H. Gordon, Ying Kuen Cheung, Bruce Levin, Howard Andrews, Carolyn Doorish, Robert B. MacArthur, Jacqueline Montes, Kate Bednarz, Julaine Florence, Julie Rowin, Kevin Boylan, Tahseen Mozaffar, Rup Tandan, Hiroshi Mitsumoto, Elizabeth A. Kelvin, John Chapin, Richard Bedlack, Michael Rivner, Leo F. McCluskey, Alan Pestronk & 9 others Michael Graves, Eric J. Sorenson, Richard Barohn, Jerry M. Belsh, Jau Shin Lou, Todd Levine, David Saperstein, Robert G. Miller, Stephen N. Scelsa

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Combining agents with different mechanisms of action may be necessary for meaningful results in treating ALS. The combinations of minocycline-creatine and celecoxib-creatine have additive effects in the murine model. New trial designs are needed to efficiently screen the growing number of potential neuroprotective agents. Our objective was to assess two drug combinations in ALS using a novel phase II trial design. We conducted a randomized, double-blind selection trial in sequential pools of 60 patients. Participants received minocycline (100 mg)-creatine (10 g) twice daily or celecoxib (400 mg)-creatine (10 g) twice daily for six months. The primary objective was treatment selection based on which combination best slowed deterioration in the ALS Functional Rating Scale-Revised (ALSFRS-R); the trial could be stopped after one pool if the difference between the two arms was adequately large. At trial conclusion, each arm was compared to a historical control group in a futility analysis. Safety measures were also examined. After the first patient pool, the mean six-month decline in ALSFRS-R was 5.27 (SD=5.54) in the celecoxib-creatine group and 6.47 (SD=9.14) in the minocycline-creatine group. The corresponding decline was 5.82 (SD=6.77) in the historical controls. The difference between the two sample means exceeded the stopping criterion. The null hypothesis of superiority was not rejected in the futility analysis. Skin rash occurred more frequently in the celecoxib-creatine group. In conclusion, the celecoxib-creatine combination was selected as preferable to the minocycline-creatine combination for further evaluation. This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents.

Original languageEnglish (US)
Pages (from-to)212-222
Number of pages11
JournalAmyotrophic Lateral Sclerosis
Volume9
Issue number4
DOIs
StatePublished - Aug 5 2008

Fingerprint

Celecoxib
Creatine
Combination Drug Therapy
Minocycline
Medical Futility
Neuroprotective Agents
Drug Combinations
Exanthema
Safety
Control Groups

Keywords

  • ALS
  • Amyotrophic lateral sclerosis
  • Celecoxib
  • Clinical trial
  • Combination therapy
  • Creatine
  • Minocycline
  • Neuroprotection
  • Selection trial

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Gordon, P. H., Cheung, Y. K., Levin, B., Andrews, H., Doorish, C., MacArthur, R. B., ... Scelsa, S. N. (2008). A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis, 9(4), 212-222. https://doi.org/10.1080/17482960802195632

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. / Gordon, Paul H.; Cheung, Ying Kuen; Levin, Bruce; Andrews, Howard; Doorish, Carolyn; MacArthur, Robert B.; Montes, Jacqueline; Bednarz, Kate; Florence, Julaine; Rowin, Julie; Boylan, Kevin; Mozaffar, Tahseen; Tandan, Rup; Mitsumoto, Hiroshi; Kelvin, Elizabeth A.; Chapin, John; Bedlack, Richard; Rivner, Michael; McCluskey, Leo F.; Pestronk, Alan; Graves, Michael; Sorenson, Eric J.; Barohn, Richard; Belsh, Jerry M.; Lou, Jau Shin; Levine, Todd; Saperstein, David; Miller, Robert G.; Scelsa, Stephen N.

In: Amyotrophic Lateral Sclerosis, Vol. 9, No. 4, 05.08.2008, p. 212-222.

Research output: Contribution to journalArticle

Gordon, PH, Cheung, YK, Levin, B, Andrews, H, Doorish, C, MacArthur, RB, Montes, J, Bednarz, K, Florence, J, Rowin, J, Boylan, K, Mozaffar, T, Tandan, R, Mitsumoto, H, Kelvin, EA, Chapin, J, Bedlack, R, Rivner, M, McCluskey, LF, Pestronk, A, Graves, M, Sorenson, EJ, Barohn, R, Belsh, JM, Lou, JS, Levine, T, Saperstein, D, Miller, RG & Scelsa, SN 2008, 'A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS', Amyotrophic Lateral Sclerosis, vol. 9, no. 4, pp. 212-222. https://doi.org/10.1080/17482960802195632
Gordon, Paul H. ; Cheung, Ying Kuen ; Levin, Bruce ; Andrews, Howard ; Doorish, Carolyn ; MacArthur, Robert B. ; Montes, Jacqueline ; Bednarz, Kate ; Florence, Julaine ; Rowin, Julie ; Boylan, Kevin ; Mozaffar, Tahseen ; Tandan, Rup ; Mitsumoto, Hiroshi ; Kelvin, Elizabeth A. ; Chapin, John ; Bedlack, Richard ; Rivner, Michael ; McCluskey, Leo F. ; Pestronk, Alan ; Graves, Michael ; Sorenson, Eric J. ; Barohn, Richard ; Belsh, Jerry M. ; Lou, Jau Shin ; Levine, Todd ; Saperstein, David ; Miller, Robert G. ; Scelsa, Stephen N. / A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. In: Amyotrophic Lateral Sclerosis. 2008 ; Vol. 9, No. 4. pp. 212-222.
@article{a74cfafc1c0a461ea590fe1315ba4e64,
title = "A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS",
abstract = "Combining agents with different mechanisms of action may be necessary for meaningful results in treating ALS. The combinations of minocycline-creatine and celecoxib-creatine have additive effects in the murine model. New trial designs are needed to efficiently screen the growing number of potential neuroprotective agents. Our objective was to assess two drug combinations in ALS using a novel phase II trial design. We conducted a randomized, double-blind selection trial in sequential pools of 60 patients. Participants received minocycline (100 mg)-creatine (10 g) twice daily or celecoxib (400 mg)-creatine (10 g) twice daily for six months. The primary objective was treatment selection based on which combination best slowed deterioration in the ALS Functional Rating Scale-Revised (ALSFRS-R); the trial could be stopped after one pool if the difference between the two arms was adequately large. At trial conclusion, each arm was compared to a historical control group in a futility analysis. Safety measures were also examined. After the first patient pool, the mean six-month decline in ALSFRS-R was 5.27 (SD=5.54) in the celecoxib-creatine group and 6.47 (SD=9.14) in the minocycline-creatine group. The corresponding decline was 5.82 (SD=6.77) in the historical controls. The difference between the two sample means exceeded the stopping criterion. The null hypothesis of superiority was not rejected in the futility analysis. Skin rash occurred more frequently in the celecoxib-creatine group. In conclusion, the celecoxib-creatine combination was selected as preferable to the minocycline-creatine combination for further evaluation. This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents.",
keywords = "ALS, Amyotrophic lateral sclerosis, Celecoxib, Clinical trial, Combination therapy, Creatine, Minocycline, Neuroprotection, Selection trial",
author = "Gordon, {Paul H.} and Cheung, {Ying Kuen} and Bruce Levin and Howard Andrews and Carolyn Doorish and MacArthur, {Robert B.} and Jacqueline Montes and Kate Bednarz and Julaine Florence and Julie Rowin and Kevin Boylan and Tahseen Mozaffar and Rup Tandan and Hiroshi Mitsumoto and Kelvin, {Elizabeth A.} and John Chapin and Richard Bedlack and Michael Rivner and McCluskey, {Leo F.} and Alan Pestronk and Michael Graves and Sorenson, {Eric J.} and Richard Barohn and Belsh, {Jerry M.} and Lou, {Jau Shin} and Todd Levine and David Saperstein and Miller, {Robert G.} and Scelsa, {Stephen N.}",
year = "2008",
month = "8",
day = "5",
doi = "10.1080/17482960802195632",
language = "English (US)",
volume = "9",
pages = "212--222",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS

AU - Gordon, Paul H.

AU - Cheung, Ying Kuen

AU - Levin, Bruce

AU - Andrews, Howard

AU - Doorish, Carolyn

AU - MacArthur, Robert B.

AU - Montes, Jacqueline

AU - Bednarz, Kate

AU - Florence, Julaine

AU - Rowin, Julie

AU - Boylan, Kevin

AU - Mozaffar, Tahseen

AU - Tandan, Rup

AU - Mitsumoto, Hiroshi

AU - Kelvin, Elizabeth A.

AU - Chapin, John

AU - Bedlack, Richard

AU - Rivner, Michael

AU - McCluskey, Leo F.

AU - Pestronk, Alan

AU - Graves, Michael

AU - Sorenson, Eric J.

AU - Barohn, Richard

AU - Belsh, Jerry M.

AU - Lou, Jau Shin

AU - Levine, Todd

AU - Saperstein, David

AU - Miller, Robert G.

AU - Scelsa, Stephen N.

PY - 2008/8/5

Y1 - 2008/8/5

N2 - Combining agents with different mechanisms of action may be necessary for meaningful results in treating ALS. The combinations of minocycline-creatine and celecoxib-creatine have additive effects in the murine model. New trial designs are needed to efficiently screen the growing number of potential neuroprotective agents. Our objective was to assess two drug combinations in ALS using a novel phase II trial design. We conducted a randomized, double-blind selection trial in sequential pools of 60 patients. Participants received minocycline (100 mg)-creatine (10 g) twice daily or celecoxib (400 mg)-creatine (10 g) twice daily for six months. The primary objective was treatment selection based on which combination best slowed deterioration in the ALS Functional Rating Scale-Revised (ALSFRS-R); the trial could be stopped after one pool if the difference between the two arms was adequately large. At trial conclusion, each arm was compared to a historical control group in a futility analysis. Safety measures were also examined. After the first patient pool, the mean six-month decline in ALSFRS-R was 5.27 (SD=5.54) in the celecoxib-creatine group and 6.47 (SD=9.14) in the minocycline-creatine group. The corresponding decline was 5.82 (SD=6.77) in the historical controls. The difference between the two sample means exceeded the stopping criterion. The null hypothesis of superiority was not rejected in the futility analysis. Skin rash occurred more frequently in the celecoxib-creatine group. In conclusion, the celecoxib-creatine combination was selected as preferable to the minocycline-creatine combination for further evaluation. This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents.

AB - Combining agents with different mechanisms of action may be necessary for meaningful results in treating ALS. The combinations of minocycline-creatine and celecoxib-creatine have additive effects in the murine model. New trial designs are needed to efficiently screen the growing number of potential neuroprotective agents. Our objective was to assess two drug combinations in ALS using a novel phase II trial design. We conducted a randomized, double-blind selection trial in sequential pools of 60 patients. Participants received minocycline (100 mg)-creatine (10 g) twice daily or celecoxib (400 mg)-creatine (10 g) twice daily for six months. The primary objective was treatment selection based on which combination best slowed deterioration in the ALS Functional Rating Scale-Revised (ALSFRS-R); the trial could be stopped after one pool if the difference between the two arms was adequately large. At trial conclusion, each arm was compared to a historical control group in a futility analysis. Safety measures were also examined. After the first patient pool, the mean six-month decline in ALSFRS-R was 5.27 (SD=5.54) in the celecoxib-creatine group and 6.47 (SD=9.14) in the minocycline-creatine group. The corresponding decline was 5.82 (SD=6.77) in the historical controls. The difference between the two sample means exceeded the stopping criterion. The null hypothesis of superiority was not rejected in the futility analysis. Skin rash occurred more frequently in the celecoxib-creatine group. In conclusion, the celecoxib-creatine combination was selected as preferable to the minocycline-creatine combination for further evaluation. This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents.

KW - ALS

KW - Amyotrophic lateral sclerosis

KW - Celecoxib

KW - Clinical trial

KW - Combination therapy

KW - Creatine

KW - Minocycline

KW - Neuroprotection

KW - Selection trial

UR - http://www.scopus.com/inward/record.url?scp=48349092132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349092132&partnerID=8YFLogxK

U2 - 10.1080/17482960802195632

DO - 10.1080/17482960802195632

M3 - Article

VL - 9

SP - 212

EP - 222

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 4

ER -